Skip to main content
. 2021 Aug 30;43(5):1311–1323. doi: 10.1038/s41401-021-00756-8

Fig. 4. Inhibition of FTO impaired osteogenic differentiation of BMSCs.

Fig. 4

a Synthesis of the FTO inhibitor FB23 and validation of its effects on osteogenic differentiation of BMSCs. b An ALP activity assay and ARS staining were performed on BMSCs treated with various concentrations of FB23 for 7 and 14 days, respectively. c Quantification of ALP activity and ARS staining in BMSCs treated with FB23 was performed with ImageJ. d Synthesis of the FTO inhibitor FB23-2 and validation of its effects on osteogenic differentiation of BMSCs. e The ALP activity assay and ARS staining were performed on BMSCs treated with various concentrations of FB23-2 for 7 and 14 days. f Quantification of ALP activity and ARS staining in BMSCs treated with FB23-2 was performed with ImageJ. g The IC50 of FB23 and FB23-2 in hMSCs after treatment for 72 h. h The mRNA expression levels of ALP and Runx2 on day 7 in hMSCs treated with FB23 and FB23-2. *P < 0.05; **P < 0.01; ***P < 0.001; n = 3.